GSK Offers Price Freeze On Ventolin HFA In Bid For Early Phase-Out Of CFCs
Executive Summary
GlaxoSmithKline has offered to freeze the wholesale price of its Ventolin HFA inhaler as part of its case for FDA to phase out chlorofluorocarbon albuterol metered-dose inhalers by December 31, 2005